Prime Medication, a biotech whose wild ambitions for a strong gene enhancing expertise sank as the biotech market slumped, introduced Monday it’s changing its CEO, shedding 25% of its employees, and scrapping its lead program.
The reorganization comes amid a chronic winter for the gene enhancing area that has seen practically each main firm lay off employees or minimize applications, generally regardless of promising knowledge. A couple of firms have shut down altogether or merged out of existence.
Prime was initially fashioned in 2019, round a CRISPR-based expertise from Broad Institute biochemist David Liu for making just about any kind of small edit to the genome: single-letter modifications, small insertions, and small deletions.
This text is unique to STAT+ subscribers
Unlock this text — plus day by day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
